IQUALBI Trademark

Trademark Overview


On Tuesday, February 1, 2022, a trademark application was filed for IQUALBI with the United States Patent and Trademark Office. The USPTO has given the IQUALBI trademark a serial number of 97247940. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Tuesday, August 27, 2024. This trademark is owned by TEVA PHARMACEUTICALS USA, Inc.. The IQUALBI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders (skin), musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations
iqualbi

General Information


Serial Number97247940
Word MarkIQUALBI
Filing DateTuesday, February 1, 2022
Status733 - FOURTH EXTENSION - GRANTED
Status DateTuesday, August 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 1, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders (skin), musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 7, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Friday, February 4, 2022NEW APPLICATION ENTERED
Monday, February 7, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 20, 2022ASSIGNED TO EXAMINER
Tuesday, September 27, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 12, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 1, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 1, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 27, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, February 22, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, February 22, 2023SOU EXTENSION 1 FILED
Wednesday, February 22, 2023SOU EXTENSION 1 GRANTED
Friday, September 1, 2023SOU TEAS EXTENSION RECEIVED
Friday, September 1, 2023SOU EXTENSION 2 FILED
Friday, September 1, 2023SOU EXTENSION 2 GRANTED
Monday, March 4, 2024SOU EXTENSION 3 GRANTED
Friday, February 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 5, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 4, 2024SOU TEAS EXTENSION RECEIVED
Monday, March 4, 2024SOU EXTENSION 3 FILED
Tuesday, March 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU EXTENSION 4 FILED
Tuesday, August 27, 2024SOU EXTENSION 4 GRANTED